LM-OVA completely inhibited the growth of OVA-carrying tumors (B16F0.OVA) in WT and KO mice, showing that, at the peak of the response, the induction of antigen-specific CD8+ T cells is successfully translated to an anti-tumor therapy irrespective of the host deficiency in either pyroptosis or necroptosis machineries. The gene discussed is CD8A; the disease is neoplasm.